Details of the Drug Reposition

General Information of This Drug (ID: DMBS3UG)

Drug Name
CORT-125134   DMBS3UG
Synonyms
relacorilant; Relacorilant; UNII-2158753C7E; 2158753C7E; 1496510-51-0; Relacorilant [INN]; Relacorilant [WHO-DD]; Relacorilant [USAN:INN]; SCHEMBL15454999; WANIDIGFXJFFEL-SANMLTNESA-N; CORT125134; ZINC141949519; AKOS032945759; J3.651.009I; ((4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoqui
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cushing disease DISOG6P2 5A70 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [2]
------------------------------------------------------------------------------------
1 Clinical trial Indication(s)
Indication Name Indication ID ICD-11 Status REF
Alcohol dependence DIS4ZSCO 6C40.2 Clinical trial [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03697109) A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)